GTx says muscle drug fails in late-stage trials

(Reuters) - GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials. A 3-mg dose of the drug, enobosarm, was tested on about 325 patients with non-small cell lung cancer - the most common form of lung cancer. There is no approved cure for cancer-induced muscle wasting which causes decreased physical function, fatigue and weight loss. (Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)



via Health News Headlines - Yahoo! News http://news.yahoo.com/gtx-says-muscle-drug-fails-stage-trials-123640198.html